Fragment 176-191 + CJC-1295 (No DAC) + Ipamorelin Blend is supplied as one laboratory research vial containing Fragment 176-191 6mg, CJC-1295 without DAC (Mod GRF 1-29) 3mg and Ipamorelin 3mg, for 12mg combined nominal content. The CJC component is the supplier-confirmed no-DAC form, also named Mod GRF 1-29; no prolonged DAC half-life is claimed. The component amounts describe the listed material rather than a human dose or prepared solution concentration. The illustrated 3ml marking refers to container capacity.
The CJC-1295 without DAC and Mod GRF 1-29 names refer to the same specified component in this catalogue entry, so the two submitted names are consolidated here. Fragment 176-191 is not automatically interchangeable with AOD9604, and findings for a modified fragment must not be attributed to this material without a sequence match.
Early hGH-fragment experiments examined glucose effects in rats. Ipamorelin has separate preclinical secretagogue evidence. These do not establish a fat-loss effect for this mixture. The references below explain the specific study context. No direct study of this exact supplied blend was identified in this review. Comparisons should distinguish individual-component evidence from mixture-specific stability, interactions and biological activity; a source link is not an endorsement or batch certification.
Match the product designation, individual component identities and stated amounts against the relevant analytical report before drawing laboratory conclusions. The SRP research chart is explanatory, and the COA, chromatography, mass-spectrometry and traceability illustrations are educational examples, not test results for this vial. For laboratory research only; not for human or veterinary use, diagnosis or treatment.
Reviews
There are no reviews yet.